<DOC>
	<DOC>NCT00674661</DOC>
	<brief_summary>Prospective, randomized multicenter study to determine the safety and effectiveness of performing corneal collagen cross-linking (CXL) using riboflavin and UVA light in eyes with ectasia after refractive surgery.</brief_summary>
	<brief_title>Corneal Collagen Cross-Linking for Ectasia (CXL)</brief_title>
	<detailed_description>Subjects are randomized to a control group or a treatment group, with the control group crossed over to the treatment group at the 3 month visit. Corneal collagen cross-linking is performed as a single treatment. Subjects are followed for 12 months after the procedure to evaluate the long term effects of corneal collagen cross-linking.</detailed_description>
	<mesh_term>Dilatation, Pathologic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis of ectasia after refractive surgery Documented ectasia on Pentacam or topography map BSCVA worse than 20/20 Must complete all study visits History of delayed wound healing History of corneal melt or corneal dystrophy</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>ectasia</keyword>
	<keyword>cross-linking</keyword>
	<keyword>crosslinking</keyword>
	<keyword>cornea</keyword>
	<keyword>riboflavin</keyword>
	<keyword>UVA</keyword>
</DOC>